103.91
price up icon0.91%   0.94
pre-market  Vorhandelsmarkt:  106.00   2.09   +2.01%
loading

Axsome Therapeutics Inc Aktie (AXSM) Neueste Nachrichten

pulisher
Jun 18, 2025

Axsome Therapeutics, Inc. (NASDAQ:AXSM) General Counsel Hunter R. Murdock Sells 7,500 Shares - MarketBeat

Jun 18, 2025
pulisher
Jun 18, 2025

Axsome therapeutics’ general counsel sells $2.28 million in stock - Investing.com

Jun 18, 2025
pulisher
Jun 18, 2025

Axsome Therapeutics, Inc. (NASDAQ:AXSM): When Will It Breakeven? - Yahoo Finance

Jun 18, 2025
pulisher
Jun 18, 2025

Axsome Therapeutics to Present SYMBRAVO® Clinical Data at the 67th Annual Scientific Meeting of the American Headache Society - Nasdaq

Jun 18, 2025
pulisher
Jun 18, 2025

Prosperity Wealth Management Inc. Buys New Stake in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat

Jun 18, 2025
pulisher
Jun 18, 2025

SYMBRAVO Breakthrough: New Data Reveals Effectiveness in CGRP-Resistant Migraine Patients - Stock Titan

Jun 18, 2025
pulisher
Jun 16, 2025

Axsome Therapeutics, Inc. (NASDAQ:AXSM) Receives $172.33 Average Target Price from Analysts - MarketBeat

Jun 16, 2025
pulisher
Jun 16, 2025

Axsome Therapeutics (AXSM) Supports Migraine Awareness and Commu - GuruFocus

Jun 16, 2025
pulisher
Jun 16, 2025

Axsome Therapeutics Proudly Supports Migraine and Headache Awareness Month Alongside the Association of Migraine Disorders - The Manila Times

Jun 16, 2025
pulisher
Jun 16, 2025

Axsome Therapeutics Partners With Migraine Association to Help 40 Million US Patients Find Better Days - Stock Titan

Jun 16, 2025
pulisher
Jun 16, 2025

GAMMA Investing LLC Purchases 21,986 Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat

Jun 16, 2025
pulisher
Jun 15, 2025

Q3 EPS Forecast for Axsome Therapeutics Decreased by Analyst - MarketBeat

Jun 15, 2025
pulisher
Jun 15, 2025

Royal Bank of Canada Has Lowered Expectations for Axsome Therapeutics (NASDAQ:AXSM) Stock Price - MarketBeat

Jun 15, 2025
pulisher
Jun 15, 2025

Axsome initiated with an Outperform at Oppenheimer on revenue boost - MSN

Jun 15, 2025
pulisher
Jun 15, 2025

Rhumbline Advisers Increases Stock Holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat

Jun 15, 2025
pulisher
Jun 14, 2025

Axsome fell after FDA refuses to review AXS-14 application - MSN

Jun 14, 2025
pulisher
Jun 14, 2025

Axsome Therapeutics (NASDAQ:AXSM) Earns Buy Rating from HC Wainwright - MarketBeat

Jun 14, 2025
pulisher
Jun 14, 2025

Equities Analysts Issue Forecasts for AXSM FY2026 Earnings - MarketBeat

Jun 14, 2025
pulisher
Jun 14, 2025

Axsome Therapeutics’ SWOT analysis: stock’s potential in CNS market By Investing.com - Investing.com Nigeria

Jun 14, 2025
pulisher
Jun 14, 2025

Axsome Therapeutics’ SWOT analysis: stock’s potential in CNS market - Investing.com

Jun 14, 2025
pulisher
Jun 14, 2025

Assenagon Asset Management S.A. Purchases 623,717 Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat

Jun 14, 2025
pulisher
Jun 14, 2025

Mark L. Jacobson Sells 25,000 Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) Stock - MarketBeat

Jun 14, 2025
pulisher
Jun 13, 2025

RBC Capital Adjusts Price Target for AXSM, Maintains Outperform - GuruFocus

Jun 13, 2025
pulisher
Jun 13, 2025

Axsome Therapeutics, Inc. (NASDAQ:AXSM) Shares Bought by Pallas Capital Advisors LLC - MarketBeat

Jun 13, 2025
pulisher
Jun 12, 2025

Needham & Company LLC Cuts Axsome Therapeutics (NASDAQ:AXSM) Price Target to $150.00 - MarketBeat

Jun 12, 2025
pulisher
Jun 12, 2025

Axsome Therapeutics (AXSM) Target Price Adjusted by RBC Capital - GuruFocus

Jun 12, 2025
pulisher
Jun 12, 2025

Axsome’s AXS-14 Gets Regulatory Setback with RTF, says Morgan Stanley - MSN

Jun 12, 2025
pulisher
Jun 12, 2025

RBC Capital Adjusts Price Target for AXSM, Maintains Outperform Rating | AXSM Stock News - GuruFocus

Jun 12, 2025
pulisher
Jun 12, 2025

Axsome Therapeutics (AXSM) Target Price Adjusted by RBC Capital | AXSM Stock News - GuruFocus

Jun 12, 2025
pulisher
Jun 12, 2025

RBC Lowers Price Target on Axsome Therapeutics to $186 From $193, Keeps Outperform Rating - MarketScreener

Jun 12, 2025
pulisher
Jun 11, 2025

Axsome Presents Positive Phase 3 Data for AXS-12 in Narcolepsy at SLEEP 2025 - HCPLive

Jun 11, 2025
pulisher
Jun 11, 2025

The Gross Law Firm Announces Class Actions on Behalf of Shareholders of OSCR, AXSM and ET - ACCESS Newswire

Jun 11, 2025
pulisher
Jun 11, 2025

13 Biotech Stocks with Huge Upside Potential - Insider Monkey

Jun 11, 2025
pulisher
Jun 11, 2025

Axsome Therapeutics Highlights Seven Presentations on AXS-12 and Solriamfetol at SLEEP 2025 Conference - Nasdaq

Jun 11, 2025
pulisher
Jun 11, 2025

Axsome Unveils Phase 3 Narcolepsy Trial Results Among 7 Major Presentations at SLEEP 2025 - Stock Titan

Jun 11, 2025
pulisher
Jun 11, 2025

Transcript : Axsome Therapeutics, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-09-2025 02 - MarketScreener

Jun 11, 2025
pulisher
Jun 10, 2025

Axsome Therapeutics, Inc. Announces Availability of Symbravo (Meloxicam and Rizatriptan) for the Acute Treatment of Migraine with or Without Aura in Adults - marketscreener.com

Jun 10, 2025
pulisher
Jun 10, 2025

Axsome Therapeutics, Inc.'s (NASDAQ:AXSM) Shift From Loss To Profit - simplywall.st

Jun 10, 2025
pulisher
Jun 10, 2025

Axsome Therapeutics Launches SYMBRAVO for Migraine Relief - TipRanks

Jun 10, 2025
pulisher
Jun 10, 2025

Deutsche Bank Adjusts Axsome Therapeutics Price Target to $185 From $190, Maintains Buy Rating - marketscreener.com

Jun 10, 2025
pulisher
Jun 10, 2025

Axsome Therapeutics (AXSM) Launches SYMBRAVO for Migraine Relief in the U.S. | AXSM Stock News - GuruFocus

Jun 10, 2025
pulisher
Jun 10, 2025

Revolutionary Migraine Drug SYMBRAVO Now Available: Fast-Acting Relief Targets Multiple Pain Pathways - Stock Titan

Jun 10, 2025
pulisher
Jun 10, 2025

Axsome Therapeutics (NASDAQ:AXSM) Given New $150.00 Price Target at Needham & Company LLC - Defense World

Jun 10, 2025
pulisher
Jun 10, 2025

Axsome Therapeutics at Goldman Sachs Conference: Strategic Growth and Challenges - Investing.com Canada

Jun 10, 2025
pulisher
Jun 09, 2025

Axsome’s fibromyalgia drug application hits FDA roadblock By Investing.com - Investing.com South Africa

Jun 09, 2025
pulisher
Jun 09, 2025

Axsome Therapeutics Stock Price, Quotes and Forecasts | NASDAQ:AXSM - Benzinga

Jun 09, 2025
$20.44
price down icon 1.45%
$36.19
price up icon 0.86%
$22.62
price up icon 6.70%
$98.24
price up icon 0.64%
$108.26
price up icon 0.70%
biotechnology ONC
$244.32
price down icon 0.34%
Kapitalisierung:     |  Volumen (24h):